Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
Use (CHMP) has rendered a positive opinion recommending marketing approval for Leqembi (lecanemab) for early Alzheimer's disease. The CHMP recommended marketing approval for Leqembi as a treatment of adult patients with early Alzheimer's disease who are apolipoprotein E e4 (ApoE e4) non-carriers or heterozygotes with confirmed amyloid pathology in Europe. A final decision from the European Commission is expected within 67 days of receipt of the CHMP opinion. Shares of Biogen have plunged 36.3% year to date compared with the industry's decline of 4.5%. Image Source: Zacks Investment Research The CHMP had earlier given a negative opinion regarding marketing approval for Leqembi for early Alzheimer's disease in July 2024. The negative opinion was reportedly due to a brain swelling side effect called amyloid-related imaging abnormalities associated with the use of anti-amyloid therapies like Leqembi. Eisai requested the CHMP to re-examine its opinion. Leqembi gained full app
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $164.00 price target on the stock, down previously from $230.00.MarketBeat
- Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $175.00 price target on the stock.MarketBeat
BIIB
Earnings
- 10/31/24 - Beat
BIIB
Sec Filings
- 12/9/24 - Form 4
- 12/9/24 - Form 4
- 12/9/24 - Form 144
- BIIB's page on the SEC website